Minnesota Glomerular Disease Program
Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller
Mission
To provide patients with glomerular disease with expert, individualized care and access to clinical trials.
Covered Diseases
- Any glomerular disease, including (but not limited to):
- Focal Segmental Glomerulosclerosis (FSGS)
- Membranous nephropathy
- Minimal change disease
- IgA nephropathy
- Immune complex mediated diseases
- For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage
Goals
- Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
- Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
- Provide patients with access to cutting-edge clinical trials.
- Facilitate translational research.
- Provide a venue for health care providers training in the care of patients with glomerular disease.
Our Team
Physicians
- Patrick H. Nachman, MD
- Michelle Rheault, MD (pediatric nephrology)
- Surabhi Thakar, MD
- Katti Woerner, DO
Clinical & Translational Research Team
- Lama Ghazi, MD - Data Management
- Elizabeth Miller, RN, BAN, PHN, CCRC - Study Coordinator
- Charlotte Quinton, RN, BSN - Study Coordinator
- Scott Rajala, CCRP - Translational Research Assistant
Ongoing Clinical Trials
FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS).
ClinicalTrials.gov
Identifier: NCT03493685
Phase 3 trial
Principal Investigator
Michelle Rheault, MD
Study Coordinator
TBD
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis(FSGS).
ClinicalTrials.gov
Identifier: NCT03536754
Phase 2
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Charlotte Quinton, RN, BSN
quint003@umn.edu
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
ClinicalTrials.gov
Identifier: NCT03703908
Phase 2 trial
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Charlotte Quinton, RN, BSN
quint003@umn.edu
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis.
ClinicalTrials.gov
Identifier: NCT03598036
Phase 2
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Charlotte Quinton, RN, BSN
quint003@umn.edu
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
IGA NEPHROPATHY
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd).
ClinicalTrials.gov
Identifier: NCT03643965
Phase 3
Principal Investigator
Surabhi Thakar, MD
Study Coordinators
Charlotte Quinton, RN, BSN
quint003@umn.edu
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN).
ClinicalTrials.gov
Identifier: NCT03608033
Phase 3
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Charlotte Quinton, RN, BSN
quint003@umn.edu
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu